News
Bioage Labs Inc. has completed IND-enabling studies for BGE-102, a structurally novel, orally available small-molecule NLRP3 ...
Researchers in the U.K. have overthrown the orthodox view that childhood cancers have a low mutation burden, opening up new ...
For the second time in as many months, the lack of statistically significant overall survival data sent shares of Summit Therapeutics Inc. sliding, despite otherwise positive findings for PD-1/VEGF ...
Atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of mortality worldwide despite advances in managing ...
The U.S. FDA granted 510(k) clearance to Distalmotion SA's Dexter, its surgical robotic system, for use in cholecystectomy in ...
Targeting CDC-like kinases 2 and 3 (CLK2 and CLK3) has emerged as an effective therapeutic strategy in cancer treatment, with several compounds currently in clinical development.
Archeus Technologies Inc. and the Wisconsin Alumni Research Foundation (WARF) have entered into a strategic collaboration to ...
Asian health care-focused private equity firm Quadria Capital announced the final close of its Fund III with $1.07 billion in ...
Despite the advancement of AI and machine learning technologies and their incorporation into cancer treatment and drug development, a lack of trust and understanding of these new approaches is ...
Hepatocellular carcinoma (HCC) is among the leading causes of cancer-related deaths worldwide due to lack of effective diagnosis at early stages and limited comprehension of its pathogenesis, thus ...
Kexing Biopharm Co. Ltd. has announced IND clearances this month by China’s National Medical Products Administration (NMPA) ...
Inmed Pharmaceuticals Inc. has divulged cannabinoid CB1 and/or CB2 receptor modulators reported to be useful for the treatment of neurodegeneration and age-related macular degeneration.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results